{"id":"NCT01256671","sponsor":"EndoCeutics Inc.","briefTitle":"DHEA Against Vaginal Atrophy - Safety Study of 12 Months","officialTitle":"DHEA Against Vaginal Atrophy - Safety Study of 12 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-12","primaryCompletion":"2012-07","completion":"2012-12","firstPosted":"2010-12-08","resultsPosted":"2017-10-18","lastUpdate":"2017-10-18"},"enrollment":530,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Vaginal Atrophy"],"interventions":[{"type":"DRUG","name":"DHEA","otherNames":["Prasterone, Dehydroepiandrosterone, Vaginorm"]}],"arms":[{"label":"DHEA","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase III trial is to assess the long-term safety of intravaginal dehydroepiandrosterone (DHEA) in non-hysterectomized postmenopausal women with vaginal atrophy aged 40 to 75 years.","primaryOutcome":{"measure":"Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium","timeFrame":"Baseline and Week 52 (or discontinuation)","effectByArm":[{"arm":"0.50% DHEA","deltaMin":421,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":41,"countries":["United States","Canada"]},"refs":{"pmids":["25771041","26725467","26509785","25968836","26972555"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":521},"commonTop":["Application site discharge","Urinary tract infection","Nasopharyngitis"]}}